Il nostro articolo è su Nature Communications! Siamo felici di aver contribuito a questo ambizioso progetto internazionale sugli ormoni steroidei nello sviluppo del cancro!

Signal transduction by receptor tyrosine kinases (RTKs) and nuclear receptors for steroid hormones is essential for body homeostasis, but the cross-talk between these receptor families is poorly understood. We observed that glucocorticoids inhibit signalling downstream of ​EGFR, an RTK. The underlying mechanism entails suppression of ​EGFR’s positive feedback loops and simultaneous triggering of negative feedback loops that normally restrain ​EGFR. Our studies in mice reveal that the regulation of ​EGFR’s feedback loops by glucocorticoids translates to circadian control of ​EGFR signalling: ​EGFR signals are suppressed by high glucocorticoids during the active phase (night-time in rodents), while ​EGFR signals are enhanced during the resting phase. Consistent with this pattern, treatment of animals bearing ​EGFR-driven tumours with a specific kinase inhibitor was more effective if administered during the resting phase of the day, when glucocorticoids are low. These findings support a circadian clock-based paradigm in cancer therapy.

Vai all’articolo originale (in inglese): Mattia Lauriola, Yehoshua Enuka, Amit Zeisel, Gabriele D’Uva, Lee Roth, Michal Sharon-Sevilla, Moshit Lindzen, Kirti Sharma, Nava Nevo, Morris Feldman, Silvia Carvalho, Hadas Cohen-Dvashi, Merav Kedmi, Nir Ben-Chetrit, Alon Chen, Rossella Solmi, Stefan Wiemann, Fernando Schmitt, Eytan Domany & Yosef Yarden. Diurnal suppression of ​EGFR signalling by glucocorticoids and implications for tumour progression and treatment. Nature Communications, 2015

 

MEDIA COVERAGE

06.10.2014 – Science Daily Tumors might grow faster at nigh


06.10.2014 – NATURE WORLD NEWS: Is Cancer Growth Nocturnal?


06.10.2014 – Softpedia: Cancer Tumors Appear to Grow Faster and Spread More Easily at Night


06.10.2014 – Medical Xpress: Tumors might grow faster at night: Hormone that keeps us alert also suppresses the spread of cancer


06.10.2014 – Senior Journal: Cancer Grows at Night, Maybe That’s When to Attack, New Study Says


07.10.2014 – Daily Mail: Cancerous tumours ‘grow faster at night’ – and drugs to fight the disease might work better during sleep, study finds


07.10.2014 – Counsel&Heal: Cancer Treatment More Efficient During Night Time:Study


07.10.2014 – Science 2.0: Cancer Might Grow Faster At Night


07.10.2014 – The Health Site: Revealed — cancer spreads during nights


07.10.2014 – bhataramedia: Tumor Dapat Tumbuh Lebih Cepat Di Malam Hari


07.10.2014 – Jews News: Israeli study: Tumors might grow more quickly at night


08.10.2014 – The Times of Israel: Tumors may grow faster at night, Israeli study shows


08.10.2014 – Journal de la Science: Les tumeurs grossiraient plus vite la nuit


08.10.2014 – Haaretz: Night time may be the right time to treat cancer, find Israeli scientists


09.10.2014 – Weizmann USA: Why Cancer Drugs May Work Better While You Sleep


09.10.2014 – Nature子刊:夜间癌细胞扩散的更快?


09.10.2014 – TIME: Why Cancer Drugs May Work Better While You Sleep


09-10-2014 – Medisite: CANCER : LES MÉDICAMENTS PLUS EFFICACES LA NUIT


10.10.2014 – TopSante: Cancer : les tumeurs se développent plus vite la nuit


10.10.2014 – Forbes: Cancer May Grow Faster While We Sleep


10.10.2014 – Jerusalem Post Tumors may grow faster at night, say Weizmann scientists


10.10.2014 – Medcenter: Una hormona que nos mantiene alerta también suprime la diseminación del cáncer


16.10.2014 – EACR (European Association for Cancer Research): TUMOURS MIGHT GROW FASTER AT NIGHT


16.10.2014 – Revista Genetica Medica: Ritmos circadianos y tratamiento contra el cáncer


17.10.2014 – University Herald: Hormone Active During Day Supresses Growth of Cancer Cells, Study


20.10.2014 – Stato Quotidiano: Ricercatrice Manfredonia: “tumori crescono più in fretta di notte”


24.10.2014 – Huffington Post: Does Cancer Grow More Aggressively at Night?

La nostra ricerca su meccanismi post-trascrizionali in cellule staminali tumorali è stata pubblicata!

Hypoxia has been long-time acknowledged as major cancer-promoting microenvironment. In such an energy-restrictive condition, post-transcriptional mechanisms gain importance over the energy-expensive gene transcription machinery. Here we show that the onset of hypoxia-induced cancer stem cell features requires the beta-catenin-dependent post-transcriptional up-regulation of CA9 and SNAI2 gene expression. In response to hypoxia, beta-catenin moves from the plasma membrane to the cytoplasm where it binds and stabilizes SNAI2 and CA9 mRNAs, in cooperation with the mRNA stabilizing protein HuR. We also provide evidence that the post-transcriptional activity of cytoplasmic beta-catenin operates under normoxia in basal-like/triple-negative breast cancer cells, where the beta-catenin knockdown suppresses the stem cell phenotype in vitro and tumor growth in vivo. In such cells, we unravel the generalized involvement of the beta-catenin-driven machinery in the stabilization of EGF-induced mRNAs, including the cancer stem cell regulator IL6. Our study highlights the crucial role of post-transcriptional mechanisms in the maintenance/acquisition of cancer stem cell features and suggests that the hindrance of cytoplasmic beta-catenin function may represent an unprecedented strategy for targeting breast cancer stem/basal-like cells.

Vai all’articolo originale (in inglese): Gabriele D’Uva*, Sara Bertoni, Mattia Lauriola, Sabrina De Carolis, Annalisa Pacilli, Laura D’Anello, Donatella Santini, Mario Taffurelli, Claudio Ceccarelli, Yosef Yarden, Lorenzo Montanaro, Massimiliano Bonafé, Gianluca Storci. Beta-Catenin/HuR Post-Transcriptional Machinery Governs Cancer Stem Cell Features in Response to Hypoxia. PloS One, 2013 (co-corresponding author)

Il nostro articolo è su JCI! Siamo felici di aver contribuito a questo progetto internazionale sull’uscita fisiologica delle cellule staminali ematopoietiche!

Regulation of hematopoietic stem and progenitor cell (HSPC) steady-state egress from the bone marrow (BM) to the circulation is poorly understood. While glycogen synthase kinase-3β (GSK3β) is known to participate in HSPC proliferation, we revealed an unexpected role in the preferential regulation of CXCL12-induced migration and steady-state egress of murine HSPCs, including long-term repopulating HSCs, over mature leukocytes. HSPC egress, regulated by circadian rhythms of CXCL12 and CXCR4 levels, correlated with dynamic expression of GSK3β in the BM. Nevertheless, GSK3β signaling was CXCL12/CXCR4 independent, suggesting that synchronization of both pathways is required for HSPC motility. Chemotaxis of HSPCs expressing higher levels of GSK3β compared with mature cells was selectively enhanced by stem cell factor-induced activation of GSK3β. Moreover, HSPC motility was regulated by norepinephrine and insulin-like growth factor-1 (IGF-1), which increased or reduced, respectively, GSK3β expression in BM HSPCs and their subsequent egress. Mechanistically, GSK3β signaling promoted preferential HSPC migration by regulating actin rearrangement and microtubuli turnover, including CXCL12-induced actin polarization and polymerization. Our study identifies a previously unknown role for GSK3β in physiological HSPC motility, dictating an active, rather than a passive, nature for homeostatic egress from the BM reservoir to the blood circulation.

Vai all’articolo originale (in inglese): Kfir Lapid, Tomer Itkin, Gabriele D’Uva, Yossi Ovadya, Aya Ludin, Giulia Caglio, Alexander Kalinkovich, Karin Golan, Ziv Porat, Massimo Zollo, Tsvee Lapidot. GSK3β regulates physiological migration of stem/progenitor cells via cytoskeletal rearrangement. The Journal of clinical investigation, 2013

Vincitori della poster session alla conferenza ISCS 2012!

Vincitori della poster session alla conferenza ISCS 2012 “The Young Investigators Stem Cell Meeting” con il progetto organizzato da Israel Stem Cell Society  (2 Dicembre 2012. Tel Aviv, Israele).

Progetto presentato: D’Uva G, Lauriola M, Rajchman D, Weisinger K, Yarden Y and Tzahor E. “Heart regeneration and tumorigenicity: oncogenic ERBB2 as a driving force”. 

Il nostro articolo è su Nature Immunology! Siamo felici di aver contribuito a questo progetto internazionale su una nuova componente della nicchia staminale ematopoietica!

Hematopoietic stem and progenitor cells (HSPCs) are regulated by various bone marrow stromal cell types. Here we identified rare activated bone marrow monocytes and macrophages with high expression of α-smooth muscle actin (α-SMA) and the cyclooxygenase COX-2 that were adjacent to primitive HSPCs. These myeloid cells resisted radiation-induced cell death and further upregulated COX-2 expression under stress conditions. COX-2-derived prostaglandin E(2) (PGE(2)) prevented HSPC exhaustion by limiting the production of reactive oxygen species (ROS) via inhibition of the kinase Akt and higher stromal-cell expression of the chemokine CXCL12, which is essential for stem-cell quiescence. Our study identifies a previously unknown subset of α-SMA(+) activated monocytes and macrophages that maintain HSPCs and protect them from exhaustion during alarm situations.

Vai all’articolo originale (in inglese): Aya Ludin, Tomer Itkin, Shiri Gur-Cohen, Alexander Mildner, Elias Shezen, Karin Golan, Orit Kollet, Alexander Kalinkovich, Ziv Porat, Gabriele D’Uva, Amir Schajnovitz, Elena Voronov, David A Brenner, Ron N Apte, Steffen Jung, Tsvee Lapidot. Monocytes-macrophages that express α-smooth muscle actin preserve primitive hematopoietic cells in the bone marrow. Nature Immunology, 2012